EVGN vs IMMX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IMMX Captures Institutional Edge (2โ1 Pillars ยท 7โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immix Biopharma, Inc. Common Stock (IMMX) driven by superior Growth & Margin, Momentum & Technical while EVGN counters with relative strength in Options & Structure. Fundamentally, EVGN trades at N/M Forward P/E with -858.2% operating margin (-60.7% YoY revenue) versus IMMX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, EVGN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against IMMX sits in BREAKDOWN (9th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EVGN | IMMX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $6.0M | $618.5M | Larger Scale | IMMX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -60.7% | +0.0% | Higher Growth | IMMX |
| Operating Margin (TTM) Profitability | -858.2% | 0.0% | Higher Margin | IMMX |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -182.8% | -27.0% | Higher ROE | IMMX |
| 52-Week Range Position Momentum | 9% ($0โ$1) | 32% ($4โ$15) | Stronger Trend | IMMX |
| Beta / 30D Volatility Risk Regime | 1.37ฮฒ ยท 138% Vol | 1.83ฮฒ ยท 83% Vol | Lower Realized Risk | IMMX |
| Unified Institutional Score Composite Signal | 44.1 / 100 (HOLD) | 50.3 / 100 (HOLD) | Higher Composite | IMMX |